What are the clinical benefits of tocilizumab for COVID-19 patients? Evidence from available case-control studies - 12/06/21
Quels sont les avantages cliniques du tocilizumab pour les patients sous COVID-19 ? Données tirées des études cas-témoins disponibles
Doi : 10.1016/j.phclin.2020.11.003
Kiarash Ghazvini 12, 1, Mohsen Karbalaei 3, 1, Masoud Keikha 1, 2, 4, ⁎ 
1 Mashhad university of medical sciences, antimicrobial resistance research center, Mashhad, Iran
2 Mashhad university of medical sciences, faculty of medicine, department of microbiology and virology, Mashhad, Iran
3 Jiroft university of medical sciences, school of medicine, department of microbiology and virology, Jiroft, Iran
4 Mashhad university of medical sciences, Student Research Committee, Mashhad, Iran
⁎Kiarash Ghazvini, Mashhad university of medical sciences, faculty of medicine, department of microbiology and virology, Mashhad, Iran.Mashhad university of medical sciences, faculty of medicine, department of microbiology and virologyMashhadIran
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
El texto completo de este artículo está disponible en PDF.
Esquema
© 2020
Elsevier Masson SAS. Reservados todos los derechos.
Vol 56 - N° 2
P. 217-221 - juin 2021 Regresar al número
Artículo precedente
- Attentat de Strasbourg, 11 décembre 2018 : retour d’expérience du service pharmacie–stérilisation
- Florelle Bertrand, Thierry Nai, Aurélie Reiter-Schatz, Amélie Schwarzenbart, Anne Dory, Raphaël Passemard, Bénédicte Gourieux
- Revue de presse : articles récents utiles à la pratique pharmaceutique
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.